Biomedical Engineering Reference
In-Depth Information
growth factor receptor.
J Clin Oncol
2004; 22: 175-184. doi:10.1200/
JCO.2004.05.114.
55. Tejpar S, Peeters M, Humblet Y,
Phase I/II study of cetuximab
dose-escalation in patients with metastatic colorectal cancer (mCRC)
with no or slight skin reactions on cetuximab standard dose treatment
(EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and
efficacy data.
et al.
2007; 25: 4037, (June 20 supplement).
56. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-
targeted agents: is there a silver lining?
J Clin Oncol
J Clin Oncol
2005; 23: 5235-
5246. doi:10.1200/JCO.2005.00.6916.
57. Bos JL, Fearon ER, Hamilton SR,
et al.
Prevalence of ras gene
mutations in human colorectal cancers.
Nature
1987; 327: 293-297.
doi:10.1038/327293a0.
58. Li J, Wang L, Mamon H,
Replacing PCR with COLD-PCR enriches
variant DNA sequences and redefines the sensitivity of genetic testing.
Nat Med
et al.
2008; 14: 579-584. Published on 20080413. doi:10.1038/
nm1708.
59. Ogino S, Kawasaki T, Brahmandam M,
Sensitive sequencing
method for KRAS mutation detection by Pyrosequencing.
et al.
J Mol Diagn
2005; 7: 413-421.
60. Clayton SJ, Scott FM, Walker J,
K-ras point mutation detection
in lung cancer: comparison of two approaches to somatic mutation
detection using ARMS allele-specific amplification.
et al.
Clin Chem
2000;
46: 1929-1938.
61. Soulieres D, Greer W, Magliocco AM,
KRAS mutation testing in the
treatment of metastatic colorectal cancer with anti-EGFR therapies.
Curr Oncol
et al.
2010; 17 Suppl 1: S31-S40.
62. Nikiforova MN, Lynch RA, Biddinger PW,
RAS point mutations
and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence
for distinct molecular pathways in thyroid follicular carcinoma.
et al.
J Clin
2003; 88: 2318-2326.
63. Dabritz J, Hanfler J, Preston R,
Endocrinol Metab
Detection of Ki-ras mutations in
tissue and plasma samples of patients with pancreatic cancer using
PNA-mediated PCR clamping and hybridisation probes.
et al.
Br J Cancer
2005; 92: 405-412. doi:10.1038/sj.bjc.6602319.
64. Al-Mulla F, Going JJ, Sowden ET,
Heterogeneity of mutant versus
wild-type Ki-ras in primary and metastatic colorectal carcinomas, and
association of codon-12 valine with early mortality.
et al.
J Pathol
1998; 185:
130-138. doi:2-M.
